NCT06001151View on ClinicalTrials.gov

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2027

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Cadonilimab

Patients receive cadonilimab (10mg/kg) every 3 weeks.

DRUG

Pemetrexed

Patients receive pemetrexed (500mg/m2) every 3 weeks.

DRUG

Carboplatin

Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.

Trial Locations (1)

430030

RECRUITING

Qian Chu, Wuhan

Sponsors
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Qian Chu

OTHER